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Description
FIELD OF THE INVENTION
[0001] THIS INVENTION relates to a method of ther-
apy of brain, spinal and nerve injury. There is also pro-
vided a formulation which is particularly useful in the-
method.
[0002] Injury to the brain results in the development of
motor and cognitive deficits that contribute to the signif-
icant morbidity experienced by survivors of brain injury.
Moreover, it is an occurrence that has the highest inci-
dence in younger members of society. Accordingly, injury
to the brain is responsible for the greatest loss of produc-
tive life as compared to any other disease process. De-
spite this, there is no effective therapy to improve out-
come after brain injury. Use of this therapy significantly
improves both motor and cognitive outcome in mild to
severe experimental brain injury and has also been found
to have beneficial effect also for the treatment of spinal
cord and nerve injuries.
BACKGROUND OF THE INVENTION
[0003] It is well known that brain injury results in the
development of neurologic deficits through two mecha-
nisms. The first of these is known as primary mecha-
nisms. These occur at the time of the injurious event and
include mechanical processes such as laceration, tear-
ing, stretching and compression of nerve fibres. Little can
be done for this type of injury once it has occurred. The
second mechanism is secondary injury, which includes
biochemical and physiological processes, initiated by a
primary injury but which manifest with time after the injury.
It has been demonstrated that much of the morbidity after
brain injury is associated with the development of this
secondary injury. Given that the secondary injury devel-
ops from minutes to days after the primary event, there
exists a window of opportunity to pharmacologically pre-
vent this type of injury and significantly improve resultant
outcome. However, the factors that make up secondary
injury must first be identified and then "antifactors" de-
veloped to inhibit the injury process.
[0004] Our studies have concentrated on identifying
secondary injury factors after brain injury and developing
interventional therapies. One of the factors that we had
previously identified1-4 as critical to determining outcome
after injury was brain magnesium ion concentration. This
ion is a regulatory factor in a number of biochemical and
physiological processes that are activated after brain in-
jury. Indeed, a decrease in the magnesium ion concen-
tration was observed to exacerbate the injury process
while an increase in the concentration of magnesium ion
was noted to attenuate the injury process and result in
an improved outcome5. The treatment of brain injury with
magnesium has since been shown to be effective1,6-10
even when administered up to 24 hours after the primary
event, and the success of the treatment in experimental
animal studies has subsequently led to clinical trials in
human brain injury.
[0005] Despite the attenuation of deficits after brain
injury with magnesium administration, it was clear that
there were still motor and cognitive deficits that persisted
after the treatment. Our attention was particularly drawn
to the fact that in younger animals, the accumulation of
water in the brain (brain swelling) was still present and
that this may present a significant risk factor. Indeed, in
a recent clinical study11, delayed brain swelling was re-
sponsible for 50% of all deaths recorded in young victims
of brain injury.
STATEMENT OF INVENTION
[0006] It therefore is an object of the invention to pro-
vide a method of-therapy in relation to brain injury and a
formulation for use in this method.
[0007] The formulation in one aspect of the invention
comprises a NK1 receptor antagonist which is N-acetyl-
L-tryptophan and a magnesium compound which is mag-
nesium sulphate, wherein the combined use of the mag-
nesium compound and the NK1 receptor antagonist re-
sults in greater protection against injury than either of the
magnesium compound or the NK1 receptor antagonist
used alone.
[0008] The method of the invention includes the step
of administration of the formulation to the patient suffering
from brain injury. Alternatively, each of the components
of the formulation are administered separately or sepa-
rated by a time delay that does not affect the effective-
ness of the therapy, e.g. 1-30 minutes.
[0009] Substance P to which the NK1 receptor antag-
onists belong is an excitatory neurotransmitter and has
a role in pain transmission and is a peptide having the
structure RPKPEEFFGLM-NH2. It is from the hypotha-
lamus, CSN and intestine and increases smooth muscle
contraction of the G1 tract.
[0010] It is known that neurokinin 1 receptor, is be-
lieved to have a role in blood travelling to the brain.
[0011] The pharmaceutical preparations in accord-
ance with this invention can in addition also contain pre-
servatives, solubilizers, sabilizers, wetting agents, emul-
sifiers, sweeteners, colorants, flavorants, salts for vary-
ing the osmotic pressure, buffers, masking agents or anti-
oxidants. They can also contain still other therapeutically
valuable substances. Thus the term "comprising" used
in the specification should be interpreted in this context.
The dosage can vary within wide limits and can, of
course, be fitted to the individual requirements in each
particular case. In general, a dosage of 1 to 20000mg
per patient, preferably 10 to 5000mg and more preferably
50 to 2000mg of the substance P receptor antagonist
should be appropriate.
[0012] In relation to the development of the inventive
concept, it was established by the present inventors that
one reason for acute water accumulation in the brain after
injury was the result of vasogenic oedema formation. This
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is caused by an increased permeability of the blood brain
barrier thus permitting vascular proteins and water to en-
ter the extracellular space in the brain and case swelling.
Few studies have examined how this increased blood
brain barrier permeability contributes to the development
of neurological deficits after injury, and no studies have
investigated whether inhibition of brain swelling improves
outcome.
[0013] We further hypothesised that administration of
a Nk1 receptor antagonist antagonist may prevent brain
swelling and the development of delayed neurologic def-
icits after injury. This hypothesis was a result of our dis-
covery referred to above, that water accumulated in the
brain as a result of vasogenic edema formation.
EXPERIMENTAL
[0014] We chose to use the compound N-acetyl-L-
tryptophan based on its low lipid solubility that limits its
ability to naturally cross the blood brain barrier and the
fact that it is relatively inexpensive. Administration of N-
acetyl-L-tryptophan at an intravenous dose of 246mg/kg
(saline vehicle) given at 30 minutes after brain injury re-
sulted in a significant improvement of cognitive outcome
in brain injured animals as assessed by the Barnes Cir-
cular Maze. Similarly, there was a significant improve-
ment in motor outcome of animals as assessed by the
otarod test. These improvements in outcome were ap-
parent at 24 hours after brain injury and persisted for the
14 day assessment period. Control (vehicle tested) ani-
mals has significantly worse neurologic outcome than
treated animals at all time points tested.
[0015] Animals treated with N-acetyl-L- tryptophan had
a significant reduction in brain water accumulation at 24
hours after injury as compared to vehicle treated controls.
This was consistent with the observation that N- acetyl-
L-tryptophan reduced brain penetration of Evans blue at
5 hours after injury, the time associated with maximum
blood brain barrier permeability after brain injury. Thus,
N-acetyl-L-tryptophan administered at 30 minutes after
brain injury reduced blood brain barrier permeability and
reduced vasogenic oedema formation. The fact that
these effects were noted with a non-permeable formula-
tion of the NK1 antagonist suggests that the effects were
largely mediated by vascular receptors and not depend-
ent upon central receptors.
[0016] Administration of N-acetyl-L- tryptophan at 24.6
mg/kg also significantly improved cognitive outcome of
brain injured animals. However, the drug had less of a
beneficial effect on motor outcome. Moreover, because
there was always some residual cognitive and motor def-
icits noted in all treated animals, the beneficial effects of
treatment with the NK1 antagonist were less apparent
when injury of mild severity was induced as opposed to
injury of a severe nature. This is a major limitation given
that mild head injury has the greatest incidence in brain
injury patients.
COMBINATION MAGNESIUM AND N-ACETYL-L- 
TRYPTOPHAN
[0017] The most common form of brain injury is mild
head injury. Guidelines to be introduced next year (2000)
by the World Federation of Neurological Surgeons will
recommend that all cases of minor head injury with any
complications such as vomiting, nausea, loss of con-
sciousness or amnesia MUST present to a hospital. This
will place considerable pressure on the health system to
adequately treat these individuals such that secondary
injury does not develop any further. Currently, there is
no such therapy.
[0018] Our results with N-acetyl-L-tryptophan suggest
that this compound closes the blood brain barrier after
head injury and reduces brain swelling or cerebral oede-
ma. This is extremely important in young victims of head
injury who are particularly vulnerable to delayed brain
swelling. Furthermore, our results with magnesium ther-
apy suggest that magnesium treatment is effective at re-
ducing neurologic deficits not necessarily associated
with increased blood brain permeability. We therefore
propose that a combination of a substance P antagonist
with a magnesium compound or salt will be a particularly
effective therapy for the treatment of brain injury irrespec-
tive of severity.
[0019] Combination administration of 246 mg/kg N-
acetyl-L-tryptophan plus 30 mg/kg magnesium sulphate
(intravenously) resulted in a profound attenuation of both
motor and cognitive deficits that was significantly greater
than obtained with either drug in isolation (FIG. 1 and
FIG. 2).
[0020] Each of the compounds in the combination for-
mulation has a number of properties that make it partic-
ularly attractive for use in brain injury.
[0021] Magnesium affects over 300 cellular enzymes.
It is not surprising, therefore, that magnesium has nu-
merous targets at which it may improve outcome. These
include, amongst others, blocking glutamate induced ex-
citotoxicity, improving membrane stability and reducing
the production of reactive oxygen species, improving en-
ergy status, inhibiting calcium channels, reducing neu-
rotransmitter release, inhibiting mitochondrial transition
pore opening, and inhibiting apoptosis. Notably, it also
blocks glutamate induced release of substance P. Phys-
iologically, magnesium has been shown14-17 to improve
cerebral blood flow, reduces cerebral vasospasms, and
reduces vascular ceramide and prostaglandin produc-
tion.
[0022] The combined use of magnesium and the sub-
stance P antagonist results in greater protection against
neural injury than either drug used alone.
[0023] We have previously shown that magnesium has
a beneficial effect in trauma when administered at intra-
venous doses ranging from 16 to 60 mg/kg. When ad-
ministered as an intramuscular injection, the effective
dose varies form 45 to 90 mg/kg. The target is to increase
free magnesium concentration in the blood to approxi-
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mately 1.0mM, which is double the normal blood free
magnesium concentration. Beneficial results are ob-
served irrespective of the magnesium salt used.
[0024] Our studies with the substance P antagonist
has demonstrated that the effective i.v. dose varies from
24.6 mg/kg to 240.6 mg/kg or higher, with the higher dos-
es having a greater beneficial effect on motor outcome.
Moreover, these doses pertain to antagonists that have
low lipid solubility and thus limited blood brain barrier
permeability. A highly lipid soluble formulation should ex-
act the same beneficial actions, however, there may be
centrally mediated side- effect that may be inappropriate.
[0025] When used in combination, the formulation may
vary in the range described for the individual compo-
nents. We have achieved excellent results using the max-
imum i.v. doses described for the individual components.
[0026] The combination magnesium/SP antagonists is
expected to be useful in the following conditions:
• As a "first-aid" prophylactic treatment following trau-
matic brain injury
• As a "first-aid" prophylactic treatment following minor
head injuries, including concussion
• As a therapy following non-traumatic brain injuries,
including stroke, hypoxia and any form of brain injury
where oedema is implicated
• As a maintenance therapy following brain injury
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Claims
1. N-acetyl-L-tryptophane and magnesium sulphate.
2. N-acetyl-L-tryptophan and magnesium sulphate for
use in medicine.
3. The use of a combination of N- acetyl-L-tryptophan
and magnesium sulphate for the preparation of a
medicament for the treatment of brain, spinal cord
and nerve injury.
4. The combination of N-acetyl-L-tryptophan and mag-
nesium sulphate for use in the treatment of brain,
spinal cord and nerve injury.
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Patentansprüche
1. N-Acetyl-L- tryptophan und Magnesiumsulfat.
2. N-Acetyl-L-tryptophan und Magnesiumsulfat zur
Verwendung in der Medizin.
3. Verwendung einer Kombination von N-Acetyl-L-
tryptophan und Magnesiumsulfat zur Herstellung ei-
nes Medikaments zur Behandlung einer Hirn-, Rük-
kenmark- und Nervenverletzung.
4. Kombination von N-Acetyl-L- tryptophan und Magne-
siumsulfat zur Verwendung bei der Behandlung ei-
ner Hirn-, Rückenmark- und Nervenverletzung.
Revendications
1. N-acétyl-L-tryptophane et sulfate de magnésium.
2. N-acétyl-L-tryptophane et sulfate de magnésium en
vue d’une utilisation en médecine.
3. Utilisation d’une combinaison de N-acétyl-L-trypto-
phane et de sulfate de magnésium pour la prépara-
tion d’un médicament destiné au traitement d’une
lésion cérébrale, spinale et nerveuse.
4. Combinaison de N- acétyl- L- tryptophane et de sulfa-
te de magnésium en vue d’une utilisation pour le
traitement d’une lésion cérébrale, spinale et nerveu-
se.
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